In a federal courthouse in downtown Phoenix right now, the Goldwater Institute is arguing that the Food and Drug Administration needs to increase transparency of its drug approval process.
The centerpiece of the argument is related to how rapidly the FDA made the drug ZMapp available to treat two doctors infected with the Ebola virus.
Before he went into court, I connected with Jon Riches. He is director of National Litigation for the Goldwatmer Institute.
I started by asking Riches why the ZMapp availability caught the Institute’s attention.
